Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy

Circulation Journal

Volumn 71, Issue 3, 2007, Pages 327-330

  Terasaki, Fumio ^a   Okamoto, Hiroshi ^b   Onishi, Katsuya ^c   Sato, Akira ^d   Shimomura, Hiroaki ^a   Tsukada, Bin ^a   Imanaka Yoshida, Kyoko ^c   Hiroe, Michiaki ^e   Yoshida, Toshimichi ^c   Kitaura, Yasushi ^a   Kitabatake, Akira ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d YOKOSUKA KYOSAI HOSPITAL   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Dilated cardiomyopathy; Heart failure; Tenascin C; Ventricular remodeling

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TENASCIN;

ADULT; ARTICLE; BLOOD SAMPLING; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; RATING SCALE; THORAX RADIOGRAPHY;

AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TENASCIN; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33947149036     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.327     Document Type: Article

References (29)

1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-842.
2. Amiya E, Tanabe K, Ikari Y, Nakajima Y, Hara K. Prolonged QRS duration and severity of mitral regurgitation are unfavorable prognostic markers of heart failure in patients with nonischemic dilated cardiomyopathy. Circ J 2006; 70: 57-62.
3. Kanzaki Y, Terasaki F, Okabe M, Hayashi T, Toko H, Shimomura H, et al. Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn Circ J 2001; 65: 797-802.
4. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation 1997; 96: 509-516.
5. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004; 90: 297-303.
6. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
7. Chiquet-Ehrismann R, Tucker RP. Connective tissues: Signalling by tenascins. Int J Biochem Cell Biol 2004; 36: 1085-1089.
8. Chiquet-Ehrismann R, Chiquet M. Tenascins: Regulation and putative functions during pathological stress. J Pathol 2003; 200: 488-499.
9. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218: 235-259.
10. Jones PL, Jones FS. Tenascin-C in development and disease: Gene regulation and cell function. Matrix Biol 2000; 19: 581-596.
11. Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, Yoshida T. The dynamic expression of tenascin-C and tenascin-X during early heart development. Differentiation 2003; 71: 291-298.
12. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001; 81: 1015-1024.
13. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996; 179: 321-325.
14. Frangogiannis NG, Shimoni S, Chang S, Ren G, Dewald O, Gersch C, et al. Active interstitial remodeling: An important process in the hibernating human myocardium. J Am Coll Cardiol 2002; 39: 1468-1474.
15. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J pathol 2005; 167: 71-80.
16. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002; 197: 388-394.
17. 111In monoclonal antibody specific for tenascin-C. Circulation 2002; 106: 1397-1402.
18. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, et al. The diagnostic utility of tenascin-C for evaluation of activity of human acute myocarditis. J Pathol 2005; 205: 460-467.
19. Sato S, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006; 47: 2319-2325.
20. Hasegawa M, Hirata H, Sudo A, Kato K, Kawase D, Kinoshita N, et al. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol 2004; 31: 2021-2026.
21. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2004; 94: 1468-1470.
22. Mann DL. Activation of inflammatory mediators in heart failure. In: Mann DL, editor. Heart failure: A companion to Braunwald's heart disease. Philadelphia: WB Saunders; 2004; 159-180.
23. Kubota T, McTienan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-635.
24. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-2059.
25. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 1999; 83: 376-382.
26. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased ciruculation cytokines in patients with cardiomyopathy and myocarditis. Br Heart J 1994; 72: 561-566.
27. Tamura A, Kusachi S, Nogami K, Yamanishi A, Kajikawa Y, Hirohata S, et al. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: Distribution along margin of fibrotic lesions. Heart 1996; 75: 291-294.
28. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: Multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 2004; 19: 517-525.
29. Ballard VL, Sharma A, Duignan I, Holm JM, Chin A, Choi R, et al. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J 2006; 20: 717-719.